AU2020228339A1 - Transdermal system for the delivery of abaloparatide and method of use - Google Patents

Transdermal system for the delivery of abaloparatide and method of use Download PDF

Info

Publication number
AU2020228339A1
AU2020228339A1 AU2020228339A AU2020228339A AU2020228339A1 AU 2020228339 A1 AU2020228339 A1 AU 2020228339A1 AU 2020228339 A AU2020228339 A AU 2020228339A AU 2020228339 A AU2020228339 A AU 2020228339A AU 2020228339 A1 AU2020228339 A1 AU 2020228339A1
Authority
AU
Australia
Prior art keywords
abaloparatide
formulation
patch
minutes
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020228339A
Other languages
English (en)
Inventor
Kenneth Brown
Lisa Dick
Ehab Hamed
Alan Harris
Gary Hattersley
Joan Moseman
Jamal SAEH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Radius Health Inc
Kindeva Drug Delivery LP
Original Assignee
Radius Health Inc
Kindeva Drug Delivery LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Radius Health Inc, Kindeva Drug Delivery LP filed Critical Radius Health Inc
Publication of AU2020228339A1 publication Critical patent/AU2020228339A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2020228339A 2019-02-28 2020-02-27 Transdermal system for the delivery of abaloparatide and method of use Abandoned AU2020228339A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962812140P 2019-02-28 2019-02-28
US62/812,140 2019-02-28
PCT/IB2020/051699 WO2020174443A1 (en) 2019-02-28 2020-02-27 Transdermal system for the delivery of abaloparatide and method of use

Publications (1)

Publication Number Publication Date
AU2020228339A1 true AU2020228339A1 (en) 2021-07-01

Family

ID=69811437

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020228339A Abandoned AU2020228339A1 (en) 2019-02-28 2020-02-27 Transdermal system for the delivery of abaloparatide and method of use

Country Status (14)

Country Link
US (1) US20210379162A1 (enExample)
EP (1) EP3930743A1 (enExample)
JP (1) JP2022521563A (enExample)
KR (1) KR20210134324A (enExample)
CN (1) CN113453704A (enExample)
AU (1) AU2020228339A1 (enExample)
BR (1) BR112021012283A2 (enExample)
CA (1) CA3122239A1 (enExample)
CO (1) CO2021007862A2 (enExample)
IL (1) IL284565A (enExample)
MX (1) MX2021007062A (enExample)
SG (1) SG11202106205YA (enExample)
TW (1) TW202037378A (enExample)
WO (1) WO2020174443A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021149012A1 (en) 2020-01-24 2021-07-29 Radius Health, Inc. Methods of stimulating bone growth with abalopartide and denosumab
CN117586377A (zh) * 2022-08-10 2024-02-23 成都奥达生物科技有限公司 一种长效阿巴洛肽化合物
CN119113134B (zh) * 2024-09-13 2025-05-16 南京羚诺生物医药技术研究院有限公司 一种提升阿巴帕肽半衰期的制备方法及其在治疗骨质疏松症中的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE416692T1 (de) * 2000-10-13 2008-12-15 Alza Corp Mikronadelelementhalter für schlagapplikator
CA2567056A1 (en) * 2004-05-10 2005-12-08 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of parathyroid hormone
CA2680690A1 (en) * 2006-03-15 2007-09-20 Alza Corporation Apparatus and method for transdermal delivery of parathyroid hormone agents to prevent or treat osteopenia
US8563513B2 (en) * 2009-03-27 2013-10-22 Van Andel Research Institute Parathyroid hormone peptides and parathyroid hormone-related protein peptides and methods of use
CA2857487C (en) * 2011-11-29 2021-09-21 Rutgers, The State University Of New Jersey Insulin-mimetics as therapeutic adjuncts for bone regeneration
US20180355319A1 (en) 2015-08-07 2018-12-13 Kyoto Prefectural Public University Corporation Method for preparing brown adipocyte
SMT202100411T1 (it) 2015-10-09 2021-11-12 Radius Health Inc Formulazioni di analoghi di pthrp, loro cerotti transdermici, e loro usi
ES2909043T3 (es) 2015-10-09 2022-05-05 Kindeva Drug Delivery Lp Composiciones de zinc para sistemas de microagujas recubiertos
AU2017253674B2 (en) * 2016-04-18 2021-07-29 Kindeva Drug Delivery L.P. Formulations of abaloparatide, transdermal patches thereof, and uses thereof

Also Published As

Publication number Publication date
SG11202106205YA (en) 2021-07-29
CN113453704A (zh) 2021-09-28
US20210379162A1 (en) 2021-12-09
EP3930743A1 (en) 2022-01-05
WO2020174443A1 (en) 2020-09-03
JP2022521563A (ja) 2022-04-11
MX2021007062A (es) 2021-09-10
KR20210134324A (ko) 2021-11-09
BR112021012283A2 (pt) 2021-09-08
TW202037378A (zh) 2020-10-16
CO2021007862A2 (es) 2021-11-19
IL284565A (en) 2021-08-31
CA3122239A1 (en) 2020-09-03

Similar Documents

Publication Publication Date Title
JP7146011B2 (ja) ＰＴＨｒＰ類似体の製剤、その経皮パッチ、およびその使用
JP7139498B2 (ja) アバロパラチドの製剤、その経皮パッチ、およびその使用
US20230277444A1 (en) FORMULATIONS OF PTHrP ANALOGUES, TRANSDERMAL PATCHES THEREOF, AND USES THEREOF
US20210379162A1 (en) Transdermal system for the delivery of abaloparatide and method of use for treating osteoporosis
US20090186052A1 (en) Use of botulinum toxin for porlonged local desensitization
HK40064524A (en) Formulations of pthrp analogues, transdermal patches thereof, and uses thereof
HK40072671A (en) Formulations of abaloparatide, transdermal patches thereof, and uses thereof
HK1260883A1 (en) Formulations of pthrp analogues. transdermal patches thereof, and uses thereof
HK40008968B (en) Formulations of abaloparatide, transdermal patches thereof, and uses thereof

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period